Vanquish Bio
Vanq Bio is pioneering innovative anti-cancer therapies utilizing Natural Killer cell-derived Extracellular Vesicle (NKEV) technology. Their mission is to transform cancer care by creating safe, effective, and accessible therapies for aggressive cancers. NKEVs target and eliminate cancer cells through apoptosis, offering enhanced stability, reduced immune evasion, and efficient tumor penetration. They are biocompatible, can cross the blood-brain barrier, and are cell-free, eliminating the risk of GVHD. Vanq Bio also researches AI-powered imaging for early detection, particularly for pancreatic cancers, integrating AI to guide targeted NKEV delivery. The company is backed by seed funding from the National Cancer Institute and their therapies are described as effective, low risk, non-toxic, affordable, and easy to ship and store.
Vanquish Bio
Vanq Bio is pioneering innovative anti-cancer therapies utilizing Natural Killer cell-derived Extracellular Vesicle (NKEV) technology. Their mission is to transform cancer care by creating safe, effective, and accessible therapies for aggressive cancers. NKEVs target and eliminate cancer cells through apoptosis, offering enhanced stability, reduced immune evasion, and efficient tumor penetration. They are biocompatible, can cross the blood-brain barrier, and are cell-free, eliminating the risk of GVHD. Vanq Bio also researches AI-powered imaging for early detection, particularly for pancreatic cancers, integrating AI to guide targeted NKEV delivery. The company is backed by seed funding from the National Cancer Institute and their therapies are described as effective, low risk, non-toxic, affordable, and easy to ship and store.